Vesalius Biocapital offers venture capital
to young European innovative life science companies
Marc Lohrmann has joined Vesalius Biocapital in January 2012 as a venture partner in the Munich office. He has 13 years experience in the life sciences sector as co-founder, investor and advisor in the area of biotech, medtech, diagnostics and agro biotech.
Marc holds a MBA of the University of Stuttgart-Hohenheim (Germany) and after his diploma thesis worked in strategy consulting. In 1999, he co-founded m-phasys, a biotech company active in the production of membrane proteins. He oversaw finance and business development as chief business officer and was i.a. responsible for raising more than EUR 10m venture capital for the company and closing strategic partnerships with e.g. Medarex.
In 2003, he joined Bayer Innovation, a corporate development vehicle of Bayer, where he was instrumental in setting up and executing the strategy in medical devices and vaccines.
During that time, he co-founded another three companies in diagnostics and medtech, most notably neurovascular medtech company Reverse Medical (Irvine, CA), which has raised more USD 20m to date and has recently sold a business unit to Covidien.
Since 2007, Marc acts as a transaction advisor to life sciences companies, e.g. M&A and licensing.